Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise

Share :
Published: 6 Dec 2015
Views: 2136
Rating:
Save
Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany

Prof Stilgenbauer presents, at a press conference at ASH 2015,  results of the pivotal international phase II study. 

Venetoclax monotherapy induces deep remissions, including complete remission and undetectable mrd, in ultra-high risk relapsed/refractory chronic lymphocytic leukaemia with 17p deletion.

Read the news story and watch the video interview for more information.